Suppr超能文献

Toll 样受体 3 有助于主动脉瓣狭窄的发展。

Toll-like receptor-3 contributes to the development of aortic valve stenosis.

机构信息

Heart Center Bonn, Clinic for Internal Medicine II, University Hospital Bonn, Bonn, Germany.

Institute of Innate Immunity, University Hospital Bonn, Bonn, Germany.

出版信息

Basic Res Cardiol. 2023 Feb 1;118(1):6. doi: 10.1007/s00395-023-00980-9.

Abstract

Aortic valve stenosis (AS) development is driven by distinct molecular and cellular mechanisms which include inflammatory pathways. Toll-like-receptor-3 (TLR3) is a lysosomal pattern-recognition receptor that binds double-stranded RNA and promotes pro-inflammatory cellular responses. In recent years, TLR3 has emerged as a major regulator of vascular inflammation. The exact role of TLR3 in the development of AS has not been investigated. Isolated human valvular interstitial cells (VICs) were stimulated with the TLR3-agonist polyIC and the resulting pro-inflammatory and pro-osteogenic response measured. Severe AS was induced in wildtype- and TLR3 mice via mechanical injury of the aortic valve with a coronary springwire. TLR3 activation was achieved by polyIC injection every 24 h after wire injury, while TLR3 inhibition was realized using Compound 4a (C4a) every 48 h after surgery. Endothelial mesenchymal transition (EndoMT) of human valvular endothelial cells (VECs) was assessed after polyIC stimulation. Stimulation of human VICs with polyIC promoted a strong inflammatory and pro-osteogenic reaction. Similarly, injection of polyIC marginally increased AS development in mice after wire injury. AS induction was significantly decreased in TLR3 mice, confirming the role of endogenous TLR3 ligands in AS pathology. Pharmacological inhibition of TLR3 with C4a not only prevented the upregulation of inflammatory cytokines and osteogenic markers in VICs, and EndoMT in VECs, but also significantly abolished the development of AS in vivo. Endogenous TLR3 activation significantly contributes to AS development in mice. Pharmacological inhibition of TLR3 with C4a prevented AS formation. Therefore, targeting TLR3 may be a viable treatment option.

摘要

主动脉瓣狭窄(AS)的发展是由不同的分子和细胞机制驱动的,其中包括炎症途径。Toll 样受体-3(TLR3)是一种溶酶体模式识别受体,可结合双链 RNA 并促进促炎细胞反应。近年来,TLR3 已成为血管炎症的主要调节剂。TLR3 在 AS 发展中的确切作用尚未得到研究。用 TLR3 激动剂 polyIC 刺激分离的人瓣膜间质细胞(VIC),并测量由此产生的促炎和促成骨反应。通过冠状动脉弹簧丝对野生型和 TLR3 小鼠的主动脉瓣进行机械损伤来诱导严重的 AS。在手术后每 48 小时用 Compound 4a(C4a)抑制 TLR3 活性,而在手术后每 24 小时用 polyIC 注射激活 TLR3。在 polyIC 刺激后评估人瓣膜内皮细胞(VEC)的内皮间充质转化(EndoMT)。polyIC 刺激人 VIC 可促进强烈的炎症和促成骨反应。同样,在弹簧丝损伤后,polyIC 的注射仅略微增加了小鼠的 AS 发展。在 TLR3 小鼠中,AS 诱导明显减少,证实了内源性 TLR3 配体在 AS 病理学中的作用。用 C4a 抑制 TLR3 的药理作用不仅防止了 VIC 中炎症细胞因子和成骨标志物以及 VEC 中的 EndoMT 的上调,而且还显著消除了体内 AS 的发展。内源性 TLR3 激活显着促进了小鼠的 AS 发展。用 C4a 抑制 TLR3 可预防 AS 形成。因此,靶向 TLR3 可能是一种可行的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd9d/9892139/81e604672675/395_2023_980_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验